Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ELAN vs TAK: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

TAK Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 8–2 Matrix Metrics)

TAK Overall Winner 6-Pillar Tally: ELAN 2 – 3 TAK (1 Tie) Matrix Metrics: ELAN 2 – 8 TAK

As of Nov 16, 2026, Takeda Pharmaceutical Company Limited (TAK) is the stronger overall head-to-head candidate over Elanco Animal Health Incorporated (ELAN) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). ELAN carries a Unified Composite Score of 33.1/100 (SELL) at $26.36 (20.8x Forward P/E, 7.7% operating margin), whereas TAK carries 48.0/100 (HOLD) at $21.61 (12.7x Forward P/E, 16.6% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ELAN vs TAK
ELAN NYSE
Elanco Animal Health Incorporated Common Stock
Pharmaceutical Preparations
$26.36
-1.59% 1D
Market Cap $13.2B
TTM Revenue $5.15B
Forward P/E 20.8x
Beta / 30D Vol 1.27β · 49% Vol
Unified Composite Score
33.1 / 100 SELL
Tech 50.0 Fund 37.0 Flow 71.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (0.9% over 20 days), RSI 64
RSI-14: 64.0 · SMA20: $24.41 · SMA50: $23.41
TAK NYSE Head-to-Head Winner
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Pharmaceutical Preparations
$21.61
+0.86% 1D
Market Cap $67.5B
TTM Revenue $25.7B
Forward P/E 12.7x
Beta / 30D Vol -0.02β · 22% Vol
Unified Composite Score
48.0 / 100 HOLD
Tech 43.0 Fund 44.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (5.9% over 20 days), RSI 72
RSI-14: 72.3 · SMA20: $20.71 · SMA50: $19.46

6-Pillar Scorecard Institutional Category Breakdown (ELAN 2 – 3 TAK)

Columns: Metric · ELAN · TAK
1. Valuation Multiples TAK
Forward P/E 20.8x 12.7x
Trailing P/E 19.6x N/M
PEG Ratio 8.94x 0.47x
EV / Revenue 3.2x 2.6x
2. Growth & Scale ELAN
Revenue Growth (YoY) +11.3% +6.7%
Earnings Growth (YoY) +440.5% -9.8%
TTM Revenue (USD) $5.15B $25.7B
Market Cap $13.2B $67.5B
3. Profitability & Quality TAK
Gross Margin 56.2% 64.8%
Operating Margin 7.7% 16.6%
Net Profit Margin -2.9% 0.9%
Return on Equity (ROE) -2.2% 0.6%
4. Balance Sheet & Cash Flow TAK
Cash Generation (TTM) $408M $7.48B EBITDA
Cash Flow Margin 7.9% 29.1% EBITDA Mgn
Net Cash / Leverage $3.24B Net Debt (0.56x D/E) $14.68 Book/Sh · 0.6% ROE
Dividend Yield None (0.00%) 2.92%
5. Options & Positioning ELAN
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 36.1% (1st %ile) 22.4% (5th %ile)
Put/Call OI Skew 13.39x (Put-Skewed) Thin ADR Chain
OBV Trend / Tech Phase ACCUMULATION · Markup NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity 48.5% of Rev ($2.50B) 48.2% of Rev ($12.4B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ELAN (2) vs TAK (8)
Institutional Metric ELAN TAK Criterion Row Edge
Market Capitalization
Scale
$13.2B $67.5B Larger Scale TAK
Trailing P/E Ratio
Valuation
19.6x N/M Lower Multiple ELAN
Forward P/E Ratio
Valuation
20.8x 12.7x Lower Multiple TAK
Revenue Growth (YoY)
Growth
+11.3% +6.7% Higher Growth ELAN
Operating Margin (TTM)
Profitability
7.7% 16.6% Higher Margin TAK
Net Profit Margin
Profitability
-2.9% 0.9% Higher Margin TAK
Return on Equity (ROE)
Capital Efficiency
-2.2% 0.6% Higher ROE TAK
52-Week Range Position
Momentum
81% ($19–$28) 97% ($14–$22) Stronger Trend TAK
Beta / 30D Volatility
Risk Regime
1.27β · 49% Vol -0.02β · 22% Vol Lower Realized Risk TAK
Unified Institutional Score
Composite Signal
33.1 / 100 (SELL) 48.0 / 100 (HOLD) Higher Composite TAK
Trailing 12M Revenue (USD)
Operating Scale
$5.15B $25.7B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
56.2% 64.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
8.94x PEG · 3.2x EV/Rev 0.47x PEG · 2.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$408M ($3.24B Net Debt (0.56x D/E)) $7.48B EBITDA ($14.68 Book/Sh · 0.6% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ELAN +2.02 pp
ELAN: +11.91% · TAK: +9.89%
3M Horizon TAK +8.27 pp
ELAN: +11.48% · TAK: +19.75%
6M Horizon ELAN +1.79 pp
ELAN: +32.24% · TAK: +30.45%
1Y Horizon TAK +31.94 pp
ELAN: +19.85% · TAK: +51.79%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ELAN vs TAK. Trailing 12-month operating profitability (ELAN 7.7% vs TAK 16.6%) and valuation multiples (ELAN 20.8x vs TAK 12.7x Forward P/E) are benchmarked directly in Pillar 4 below.

ELAN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$5.15B
Gross Margin56.2%
Op. Margin7.7%
ROE / Fwd P/E-2.2% · 20.8x
TAK ADR TTM Benchmark FX-Normalized USD
TTM Revenue$25.7B
Gross Margin64.8%
Op. Margin16.6%
ROE / Fwd P/E0.6% · 12.7x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ELAN CONSOLIDATION
76d in phase · OBV ACCUMULATION
Current IV 36.1%
IV Percentile 1st %ile
Put/Call OI Skew 13.39x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact ELAN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
TAK UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 22.4%
IV Percentile 5th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact TAK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ELAN Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $13.2B market capitalization and 7.7% operating margin.
OpEx & R&D Reinvestment 48.5% of Rev ($2.50B)
90D Engineering Disclosures 0 Published
TAK Moat Profile Scale & Operating Efficiency Moat
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $67.5B market capitalization and 16.6% operating margin.
OpEx & R&D Reinvestment 48.2% of Rev ($12.4B)
90D Engineering Disclosures 0 Published

Investor FAQ ELAN vs TAK Key Questions & Quantitative Answers

As of Nov 16, 2026, Takeda Pharmaceutical Company Limited (TAK) is the stronger overall head-to-head candidate over Elanco Animal Health Incorporated (ELAN) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). ELAN carries a Unified Composite Score of 33.1/100 (SELL) at $26.36 (20.8x Forward P/E, 7.7% operating margin), whereas TAK carries 48.0/100 (HOLD) at $21.61 (12.7x Forward P/E, 16.6% operating margin). Technically, ELAN sits in a Markup phase (RSI 64.0, CONSOLIDATION options structure) and TAK sits in a Markup phase (RSI 72.3, UNCLASSIFIED options structure).

ELAN leads the Growth & Scale pillar: ELAN posts +11.3% YoY revenue growth and +440.5% YoY earnings growth on $5.15B TTM revenue (56.2% gross margin, 7.7% operating margin), compared with TAK at +6.7% YoY revenue growth and -9.8% YoY earnings growth on $25.7B TTM revenue (64.8% gross margin, 16.6% operating margin). On trailing 12-month operating scale, ELAN generates $5.15B in USD-normalized revenue versus $25.7B for TAK. In operating R&D and SG&A reinvestment, ELAN deploys 48.5% of Rev ($2.50B) (0 90-day corporate R&D disclosures) versus 48.2% of Rev ($12.4B) (0 disclosures) for TAK.

TAK screens cheaper on headline valuation multiples. ELAN trades at 20.8x Forward P/E, 19.6x Trailing P/E, 8.94x PEG, and 3.2x EV/Revenue (7.9% FCF margin), whereas TAK trades at 12.7x Forward P/E, N/M Trailing P/E, 0.47x PEG, and 2.6x EV/Revenue (29.1% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ELAN (-2.2% ROE) versus TAK (0.6% ROE) capital efficiency.

In options market volatility and institutional positioning, ELAN carries 36.1% implied volatility (1st %ile, Compressed (<25th %ile)), a 13.39x (Put-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.27β · 49% Vol realized risk). By comparison, TAK carries 22.4% implied volatility (5th %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.02β · 22% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Elanco Animal Health Incorporated Common Stock (ELAN) Research Suite

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Research Suite

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.